AstraZeneca plc vs Western Digital Corp — how do they compare? AstraZeneca plc trades at $158 (market cap $248.14B), while Western Digital Corp trades at $455.01 (market cap $150.95B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | WDC | |
|---|---|---|
Market Cap | $248.14B | $150.95B |
Sector | Health | Technology |
52-Week High | $209.48 | $746.23 |
52-Week Low | $147.06 | $74.66 |
Enterprise Value | $275.41B | $150.42B |
Dividend Yield | 2.01% | 0.14% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Western Digital (WDC) trades at $438.12, up 0.88% on the day, with strong recent earnings performance beating expectations for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 72.95% net income margin and 131.02% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, though the stock faces valuation concerns after recent sell-offs.
The outlook remains positive with 72% analyst buy ratings and $665 consensus price target, representing 52% upside potential. Key risks include stretched valuation metrics (P/E 18.04, EV/EBITDA 30.24) and competitive threats from SSD adoption. The company's strong AI storage positioning and margin expansion provide growth opportunities, but investors should monitor execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →